Your browser doesn't support javascript.
loading
Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2.
Peric, Stojan; Zlatar, Jelena; Nikolic, Luka; Ivanovic, Vukan; Pesovic, Jovan; Petrovic Djordjevic, Ivana; Sreckovic, Svetlana; Savic-Pavicevic, Dusanka; Meola, Giovanni; Rakocevic-Stojanovic, Vidosava.
Afiliação
  • Peric S; Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
  • Zlatar J; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Nikolic L; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Ivanovic V; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Pesovic J; Neurology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
  • Petrovic Djordjevic I; Center for Human Molecular Genetics, Faculty of Biology, University of Belgrade, Belgrade, Serbia.
  • Sreckovic S; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Savic-Pavicevic D; Cardiology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
  • Meola G; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Rakocevic-Stojanovic V; Anaesthesiology Clinic, University Clinical Center of Serbia, Belgrade, Serbia.
Front Neurol ; 13: 932883, 2022.
Article em En | MEDLINE | ID: mdl-35923829
Introduction: Myotonic dystrophy type 2 (DM2) is a rare autosomal dominant multisystemic disease with highly variable clinical presentation. Several case reports and one cohort study suggested a significant association between DM2 and autoimmune diseases (AIDs). Aim: The aim of this study is to analyze the frequency and type of AIDs in patients with DM2 from the Serbian DM registry. Patients and Methods: A total of 131 patients with DM2 from 108 families were included, [62.6% women, mean age at DM2 onset 40.4 (with standard deviation 13) years, age at entering the registry 52 (12.8) years, and age at analysis 58.4 (12.8) years]. Data were obtained from Akhenaten, the Serbian registry for DM, and through the hospital electronic data system. Results: Upon entering the registry, 35 (26.7%) of the 131 patients with DM2 had AIDs including Hashimoto thyroiditis (18.1%), rheumatoid arthritis, diabetes mellitus type 1, systemic lupus, Sjogren's disease, localized scleroderma, psoriasis, celiac disease, Graves's disease, neuromyelitis optica, myasthenia gravis, and Guillain-Barre syndrome. At the time of data analysis, one additional patient developed new AIDs, so eventually, 36 (28.8%) of 125 DM2 survivors had AIDs. Antinuclear antibodies (ANAs) were found in 14 (10.7%) of 63 tested patients, including 12 without defined corresponding AID (all in low titers, 1:40 to 1:160). Antineutrophil cytoplasmic antibodies (ANCAs) were negative in all 50 tested cases. The percentage of women was significantly higher among patients with AIDs (82.9% vs. 55.2%, p <0.01). Conclusion: AIDs were present in as high as 30% of the patients with DM2. Thus, screening for AIDs in DM2 seems reasonable. Presence of AIDs and/or ANAs may lead to under-diagnosis of DM2.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article